Matches in SemOpenAlex for { <https://semopenalex.org/work/W2025921295> ?p ?o ?g. }
- W2025921295 endingPage "2420" @default.
- W2025921295 startingPage "2402" @default.
- W2025921295 abstract "Acute Myeloid Leukemia (AML) is a predominant acute leukemia among adults, characterized by accumulation of malignantly transformed immature myeloid precursors. A very attractive way to treat myeloid leukemia, which is now called ‘differentiation therapy’, was proposed as in vitro studies have shown that a variety of agents stimulate differentiation of the cell lines isolated from leukemic patients. One of the differentiation-inducing agents, all-trans retinoic acid (ATRA), which can induce granulocytic differentiation in myeloid leukemic cell lines, has been introduced into clinics to treat patients with acute promyelocytic leukemia (APL) in which a PML-RARA fusion protein is generated by a t(15;17)(q22;q12) chromosomal translocation. Because differentiation therapy using ATRA has significantly improved prognosis for patients with APL, many efforts have been made to find alternative differentiating agents. Since 1,25-dihydroxyvitamin D3 (1,25D) is capable of inducing in vitro monocyte/macrophage differentiation of myeloid leukemic cells, clinical trials have been performed to estimate its potential to treat patients with AML or myelodysplastic syndrome (MDS). Unfortunately therapeutic concentrations of 1,25D can induce potentially fatal systemic hypercalcemia, thus limiting clinical utility of that compound. Attempts to overcome this problem have focused on the synthesis of 1,25D analogs (VDAs) which retain differentiation inducing potential, but lack its hypercalcemic effects. This review aims to discuss current problems and potential solutions in differentiation therapy of AML." @default.
- W2025921295 created "2016-06-24" @default.
- W2025921295 creator A5015147430 @default.
- W2025921295 creator A5080991297 @default.
- W2025921295 date "2011-05-16" @default.
- W2025921295 modified "2023-10-01" @default.
- W2025921295 title "Differentiation Therapy of Acute Myeloid Leukemia" @default.
- W2025921295 cites W144423133 @default.
- W2025921295 cites W148052780 @default.
- W2025921295 cites W1481633630 @default.
- W2025921295 cites W1542112366 @default.
- W2025921295 cites W1553544241 @default.
- W2025921295 cites W1592847642 @default.
- W2025921295 cites W1687574083 @default.
- W2025921295 cites W1796660362 @default.
- W2025921295 cites W194185434 @default.
- W2025921295 cites W1964079616 @default.
- W2025921295 cites W1965388358 @default.
- W2025921295 cites W1966396612 @default.
- W2025921295 cites W1967103142 @default.
- W2025921295 cites W1969441758 @default.
- W2025921295 cites W1970944439 @default.
- W2025921295 cites W1971028883 @default.
- W2025921295 cites W1972576513 @default.
- W2025921295 cites W1974002977 @default.
- W2025921295 cites W1974839297 @default.
- W2025921295 cites W1975647987 @default.
- W2025921295 cites W1978409242 @default.
- W2025921295 cites W1979287544 @default.
- W2025921295 cites W1979895333 @default.
- W2025921295 cites W1985615373 @default.
- W2025921295 cites W1986974750 @default.
- W2025921295 cites W1988080543 @default.
- W2025921295 cites W1989252518 @default.
- W2025921295 cites W1989867979 @default.
- W2025921295 cites W1990904266 @default.
- W2025921295 cites W1993423079 @default.
- W2025921295 cites W1993558704 @default.
- W2025921295 cites W1995369623 @default.
- W2025921295 cites W1996441871 @default.
- W2025921295 cites W1996468867 @default.
- W2025921295 cites W2001142914 @default.
- W2025921295 cites W2002857704 @default.
- W2025921295 cites W2004294093 @default.
- W2025921295 cites W2007160987 @default.
- W2025921295 cites W2007978249 @default.
- W2025921295 cites W2009774822 @default.
- W2025921295 cites W2012415589 @default.
- W2025921295 cites W2013966572 @default.
- W2025921295 cites W2015095236 @default.
- W2025921295 cites W2016086822 @default.
- W2025921295 cites W2017570593 @default.
- W2025921295 cites W2018374421 @default.
- W2025921295 cites W2019311371 @default.
- W2025921295 cites W2019937507 @default.
- W2025921295 cites W2020048876 @default.
- W2025921295 cites W2020326102 @default.
- W2025921295 cites W2021033166 @default.
- W2025921295 cites W2021395683 @default.
- W2025921295 cites W2023033376 @default.
- W2025921295 cites W2023546573 @default.
- W2025921295 cites W2024868532 @default.
- W2025921295 cites W2027085235 @default.
- W2025921295 cites W2033718586 @default.
- W2025921295 cites W2034026805 @default.
- W2025921295 cites W2035576418 @default.
- W2025921295 cites W2036639816 @default.
- W2025921295 cites W2038248421 @default.
- W2025921295 cites W2038538357 @default.
- W2025921295 cites W2041240181 @default.
- W2025921295 cites W2041992860 @default.
- W2025921295 cites W2042117566 @default.
- W2025921295 cites W2042331757 @default.
- W2025921295 cites W2042871069 @default.
- W2025921295 cites W2043573331 @default.
- W2025921295 cites W2044228395 @default.
- W2025921295 cites W2044294015 @default.
- W2025921295 cites W2046085403 @default.
- W2025921295 cites W2049362524 @default.
- W2025921295 cites W2051492785 @default.
- W2025921295 cites W2056465113 @default.
- W2025921295 cites W2057986625 @default.
- W2025921295 cites W2059382687 @default.
- W2025921295 cites W2063083122 @default.
- W2025921295 cites W2063667483 @default.
- W2025921295 cites W2066756232 @default.
- W2025921295 cites W2067200597 @default.
- W2025921295 cites W2067436773 @default.
- W2025921295 cites W2073670968 @default.
- W2025921295 cites W2074403047 @default.
- W2025921295 cites W2075179204 @default.
- W2025921295 cites W2076067574 @default.
- W2025921295 cites W2076426515 @default.
- W2025921295 cites W2076876458 @default.
- W2025921295 cites W2077009961 @default.
- W2025921295 cites W2077916974 @default.
- W2025921295 cites W2077994180 @default.
- W2025921295 cites W2080197110 @default.